The Line in the Sand Over Personalized Medicine Is Drawn | GenomeWeb

Warfarin will soon have a label saying that people with certain genetic variations should start off with a lower initial dose of the blood thinner, reports the Wall Street Journal. Adding this label is part of the Food and Drug Administration's push to promote using genetics to predict patient's reactions to medicine, a major tenet of personalized medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.